RNA-Based Therapy for Adrenal Disorders: Mechanisms, Clinical Evidence, and Future Directions

Abstract

RNA-based therapies are rapidly emerging as a transformative approach in the management of adrenal disorders, offering precision targeting of disease pathways previously considered undruggable. This review synthesizes the current understanding of RNA therapeutics, including small interfering RNA (siRNA), antisense oligonucleotides (ASOs), and messenger RNA (mRNA), within the context of adrenal pathologies such as congenital adrenal hyperplasia (CAH), adrenal insufficiency, and adrenal neoplasms. We discuss disease burden, molecular mechanisms, clinical manifestations, diagnostic advances, and the evolving landscape of treatment. Special attention is given to translational research, ongoing clinical trials, and guideline recommendations, with the objective of equipping clinicians and researchers with actionable insights for future patient care.

Introduction

Adrenal disorders encompass a spectrum of conditions affecting hormone synthesis, secretion, and action, often leading to significant morbidity and mortality if not promptly diagnosed and effectively managed. The last decade has witnessed an explosion in molecular research, elucidating the genetic and epigenetic underpinnings of adrenal diseases. Traditional therapies, while effective for many, fall short in targeting the root molecular causes, highlighting an urgent need for innovative strategies. RNA-based therapy has emerged as a promising frontier, capable of modulating gene expression at the post-transcriptional level, thus providing a novel paradigm in the personalized treatment of adrenal disorders. This review aims to comprehensively examine recent advances, clinical trial data, and practical implications of RNA therapeutics in adrenal medicine.

Epidemiology / Disease Burden

Adrenal disorders, including CAH, Addison’s disease, adrenal Cushing’s syndrome, and adrenal tumors, collectively affect millions worldwide. CAH alone has an incidence of approximately 1 in 15,000 live births, while primary adrenal insufficiency affects 100–140 individuals per million. Adrenal neoplasms, both benign and malignant, present additional diagnostic and therapeutic challenges. The global burden is compounded by diagnostic delays, lifelong treatment requirements, and complications such as cardiovascular disease, metabolic syndrome, and impaired quality of life. Genotype-phenotype correlations and population-based studies reveal significant regional and ethnic variability, underlining the importance of precision medicine in addressing unmet clinical needs.

Pathophysiology

The pathophysiology of adrenal disorders is heterogeneous, encompassing inherited enzyme deficiencies (e.g., 21-hydroxylase deficiency in CAH), autoimmune destruction (as in Addison’s disease), and genetic mutations driving tumorigenesis (e.g., PRKAR1A mutations in Carney complex). Aberrant gene expression, defective mRNA splicing, and dysregulated microRNA (miRNA) networks contribute significantly to disease onset and progression. RNA-based therapies exploit these mechanisms by silencing mutant alleles, restoring deficient gene products, or modulating post-transcriptional gene regulation. The precision and flexibility of RNA therapeutics enable the targeting of previously inaccessible molecular nodes, offering new hope for conditions refractory to conventional therapies.

Risk Factors

Risk factors for adrenal disorders include genetic predisposition, consanguinity (notably in CAH), autoimmune diatheses, chronic infections, malignancy, and exposure to cytotoxic agents. Environmental triggers, such as stress and infections, may precipitate adrenal crises in susceptible individuals. In adrenal tumors, somatic and germline mutations, familial syndromes (e.g., MEN1, Li-Fraumeni), and epigenetic modifiers play crucial roles. Recognizing these risk factors is vital for early diagnosis, genetic counseling, and the identification of candidates most likely to benefit from RNA-based interventions.

Clinical Features

Clinical presentations of adrenal disorders vary from subtle endocrine disturbances to life-threatening crises. CAH typically manifests as ambiguous genitalia, salt-wasting crises, and precocious puberty. Addison’s disease presents with fatigue, hyperpigmentation, hypotension, and electrolyte imbalances. Adrenal tumors may be hormonally silent or cause Cushingoid features, virilization, or hypertension. RNA-based therapies, by precisely modulating pathogenic gene expression, hold the potential for symptom amelioration, reduced treatment burden, and improved quality of life, particularly in patients with refractory or genetically driven disease phenotypes.

Diagnosis

Diagnostic evaluation integrates biochemical assays (e.g., serum cortisol, ACTH, 17-hydroxyprogesterone), hormonal stimulation tests, imaging (CT, MRI), and increasingly, molecular genetic testing. Next-generation sequencing has revolutionized the identification of pathogenic variants, enabling early diagnosis, risk stratification, and therapeutic targeting. Advances in transcriptomics and miRNA profiling offer novel biomarkers for disease activity and therapeutic response, paving the way for individualized RNA-based interventions. The integration of molecular diagnostics with clinical phenotyping underpins a precision medicine approach in adrenal disease management.

Treatment & Management

Standard management of adrenal disorders relies on hormone replacement, surgical intervention, and tumor-directed therapies. Glucocorticoid and mineralocorticoid replacement remain mainstays for CAH and Addison’s disease, while adrenal tumors may require surgical resection, mitotane, or cytotoxic chemotherapy. Despite advances, many patients experience suboptimal outcomes due to inadequate disease control, side effects, or resistance to therapy. RNA-based therapeutics, such as siRNA and ASOs, offer a mechanism-based approach by targeting mutant transcripts or correcting splicing defects. Early-phase trials in CAH and preclinical studies in adrenal tumors demonstrate proof-of-concept efficacy, heralding a new era in tailored therapy.

Recent Advances / Emerging Therapies

Recent years have seen the advent of several RNA-based modalities, including siRNA targeting CYP21A2 mutations in CAH, ASO-mediated suppression of pathogenic transcripts in adrenal neoplasms, and mRNA replacement for steroidogenic enzyme deficiencies. Lipid nanoparticle delivery systems and ligand-conjugated platforms have improved tissue specificity and reduced off-target effects. Clinical trials evaluating these agents have reported promising safety and efficacy profiles, with ongoing studies poised to refine dosing, durability, and long-term outcomes. Moreover, CRISPR-based gene editing and RNA aptamers represent exciting future directions with the potential to achieve durable disease modification.

Guideline Recommendations

While mainstream guidelines from the Endocrine Society and international consortia still prioritize established therapies, they increasingly acknowledge the potential of RNA-based approaches, particularly for genetically defined or refractory cases. Expert consensus highlights the importance of multidisciplinary evaluation, genetic counseling, and enrollment in clinical trials for patients considered for RNA therapeutics. Continued collaboration between clinicians, researchers, and regulatory agencies is essential for the safe and effective integration of these novel modalities into routine care.

Conclusion

RNA-based therapies represent a paradigm shift in the management of adrenal disorders, offering unprecedented opportunities for precision targeting of disease-causing genes and pathways. While challenges remain in delivery, immunogenicity, and long-term efficacy, ongoing research and clinical trials are rapidly advancing the field. Clinicians should remain abreast of these developments, engage in shared decision-making with patients, and consider participation in research initiatives to accelerate the translation of RNA therapeutics from bench to bedside. The future of adrenal disorder management will likely be defined by a combination of molecular diagnostics, personalized interventions, and multidisciplinary care, with RNA-based therapy at the forefront of innovation.